The role of procalcitonin in the follow-up of medullary thyroid cancer
European Thyroid Journal · 2023
DOI: 10.1530/etj-22-0161 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Thyroid Journal, 2023. Verfasst von Simona Censi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Bone Density Conservation Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Calcitonin (Ct) represents the most important biochemical marker of medullary thyroid cancer (MTC), but has certain limits. We analyzed the performance of procalcitonin (ProCt) in follow-up MTC patients.
Methods
In this monocentric and retrospective study, we consecutively obtained ProCt and Ct values from all MTC patients that we visited during the period from April 2021 to May 2022. Patients were defined as having structural evidence of disease (29/90, 32.2%) irrespective of Ct values or, in its absence, as not evident disease (NED) if Ct was ≤10 ng/L (47/90, 52.2%), or minimal residual disease if Ct was >10 ng/L (14/90, 15.6%).
Results
Ct and ProCt values were highly correlated (r = 0.883, P < 0.01). Median ProCt values differed between NED, minimal residual disease, and structural disease, being 0.04 ng/mL, 0.26 ng/mL, and 1.98 ng/mL, respectively ( P < 0.01). ProCt was undetectable (0.12 ng/mL ( P < 0.01, area under the curve: 0.963), with the following sensitivity, specificity, positive predictive value, and negative predictive value (NPV): 100%, 83.61%, 74.4%, and 100.0%.
Conclusions
ProCt and Ct have a high correlation in MTC follow-up. ProCt may be useful as an adjunct to Ct, especially for its NPV concerning the structural disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
- Endocrine Surgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua, Padua, Italy.
- Laboratory Medicine, Department of Medicine (DIMED), University of Padua, Padua, Italy.
- Hereditary Tumor Unit, Istituto Oncologico Veneto, IOV - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy.
ORCID-Profile: Caterina Mian
Zitieren
APA
Censi, S., Manso, J., Benvenuti, T., Piva, I., Iacobone, M., Mondin, A., Torresan, F., Basso, D., Crivellari, G., Zovato, S., & Mian, C. (2023). The role of procalcitonin in the follow-up of medullary thyroid cancer. European Thyroid Journal. https://doi.org/10.1530/etj-22-0161
Vancouver
Censi S, Manso J, Benvenuti T, Piva I, Iacobone M, Mondin A, et al. The role of procalcitonin in the follow-up of medullary thyroid cancer. European Thyroid Journal. 2023. doi:10.1530/etj-22-0161
BibTeX
@article{Censi2023,
author = {Censi, Simona and Manso, Jacopo and Benvenuti, Teresa and Piva, Ilaria and Iacobone, Maurizio and Mondin, Alberto and Torresan, Francesca and Basso, Daniela and Crivellari, Gino and Zovato, Stefania and Mian, Caterina},
title = {The role of procalcitonin in the follow-up of medullary thyroid cancer},
journal = {European Thyroid Journal},
year = {2023},
doi = {10.1530/etj-22-0161}
}
EUVIMED